- Home
- NLSP vs CNSP Comparison
NLSP vs CNSP Comparison
Compare NLSP & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- CNSP
- Stock Information
- Founded
- NLSP 2015
- CNSP 2017
- Country
- NLSP Switzerland
- CNSP United States
- Employees
- NLSP N/A
- CNSP N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- CNSP Health Care
- Exchange
- NLSP Nasdaq
- CNSP Nasdaq
- Market Cap
- NLSP 6.2M
- CNSP 6.5M
- IPO Year
- NLSP 2021
- CNSP 2019
- Fundamental
- Price
- NLSP $1.95
- CNSP $3.23
- Analyst Decision
- NLSP
- CNSP Strong Buy
- Analyst Count
- NLSP 0
- CNSP 1
- Target Price
- NLSP N/A
- CNSP $0.50
- AVG Volume (30 Days)
- NLSP 6.1M
- CNSP 941.1K
- Earning Date
- NLSP 10-18-2024
- CNSP 03-31-2025
- Dividend Yield
- NLSP N/A
- CNSP N/A
- EPS Growth
- NLSP N/A
- CNSP N/A
- EPS
- NLSP N/A
- CNSP N/A
- Revenue
- NLSP N/A
- CNSP N/A
- Revenue This Year
- NLSP N/A
- CNSP N/A
- Revenue Next Year
- NLSP N/A
- CNSP N/A
- P/E Ratio
- NLSP N/A
- CNSP N/A
- Revenue Growth
- NLSP N/A
- CNSP N/A
- 52 Week Low
- NLSP $1.71
- CNSP $2.81
- 52 Week High
- NLSP $18.40
- CNSP $1,195.00
- Technical
- Relative Strength Index (RSI)
- NLSP 44.06
- CNSP 35.22
- Support Level
- NLSP $2.14
- CNSP $4.60
- Resistance Level
- NLSP $2.34
- CNSP $9.50
- Average True Range (ATR)
- NLSP 0.24
- CNSP 0.94
- MACD
- NLSP -0.00
- CNSP -0.15
- Stochastic Oscillator
- NLSP 12.07
- CNSP 6.28
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.